From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IL6
Clinical data
ATC code
  • none
CAS Number
  • none
 NYesY (what is this?)  (verify)

Olokizumab is an immunomodulator. It binds to interleukin 6.[1] Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA).

It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe RA.[2][3]


  1. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information. 
  2. ^ Another IL-6 Blocker in RA
  3. ^ Genovese, MC (2014). "Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study". Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204760. Retrieved 21 February 2016.